ZT002 Injection

DRUG4 trials

Sponsors

Beijing QL Biopharmaceutical Co.,Ltd

Conditions

Overweight or ObesityOverweight, ObesityType 2 Diabetes

Phase 1

A Study of ZT002 Injection in Participants With Overweight or Obesity

CompletedNCT06371326

Beijing QL Biopharmaceutical Co.,LtdOverweight or Obesity

Start: 2023-11-21End: 2024-10-17Updated: 2026-01-16

A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT07065032

Beijing QL Biopharmaceutical Co.,LtdType 2 Diabetes

Start: 2024-02-19End: 2024-08-05Updated: 2025-07-15

A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults

Not yet recruitingNCT07697846

Beijing QL Biopharmaceutical Co.,LtdOverweight, Obesity

Start: 2026-07-18End: 2027-03-24Target: 40Updated: 2026-07-13

Phase 2

A Study of ZT002 Injection With Subjects With Overweight or Obesity

CompletedNCT07020884

Beijing QL Biopharmaceutical Co.,LtdOverweight or Obesity

Start: 2024-08-14End: 2025-05-29Updated: 2025-12-10